The completion of the sequencing of the human genome in 2000 was a landmark event, opening up new opportunities to derive meaning from the three billion letters in this “Instruction Book of Life.” Affymetrix stands at the gateway of functional genomics by providing tools that help decipher sequence information through the understanding of gene expression and genetic variability. Using our unique GeneChip® technology, researchers can download massive amounts of DNA information and use it to study a large percentage of the human genome in a single experiment.

Since its founding in 1991, Affymetrix has been driven by a vision of providing powerful and versatile tools for large-scale biological research. Numerous scientific studies and thousands of GeneChip array users have since validated this vision and established GeneChip technology as the gold standard in the DNA array field. With as many as 400,000 unique probes corresponding to thousands of genes of interest, these commercially-available GeneChip arrays offer unprecedented speed, efficiency and cost-effectiveness for conducting gene function studies that can provide answers to complex biological questions.

These technological achievements position Affymetrix to capitalize on current trends in genomics. The only company with a commercially successful high-density array platform, Affymetrix is unique in its ability to deliver products for whole genome analysis — the key to understanding and interpreting the vast amount of new human and other genome sequence data that are now becoming available. Going forward, the Company will leverage these powerful capabilities through a strong focus on whole genome products. Combined with a commitment to providing researchers with a total system solution, this strategy should enable Affymetrix to maintain its technological, scientific and commercial leadership in the DNA array field.

< Back to Top